PAHCPAHCHealthcare · Drug Manufacturers - Specialty & Generic

PAHC Stock Forecast: Phibro Animal Health Corp. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$36
+1.89% on the day

The 3 Wall Street analysts covering Phibro Animal Health Corp. hold a median 12-month price target of $49 — +37.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 17 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.4B
Ticker Nerd rank
92/ 100
Median analyst target
$49
Analysts covering
3
Revenue$396.7M+4.8% y/y
Operating income$48.2M
Net income$21.7M
Free cash flow$5.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.2%
1M
−8.3%
YTD
−4.0%
1Y
−17.1%
From 52W high
−39.9%
From 52W low
+25.5%
$28
$59
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PAHC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Phibro Animal Health Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
92/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
97
Quality
95
Revisions
89
Volatility
88
Growth
70
Momentum
69
Issuance
59
Size
39
Accruals
22

Value (97): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (22): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PAHC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PAHC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$25$30$35$40$45$50$55$60Jan 26Apr 26Jul 26Oct 26PAHCHigh $55Median $49Low $37

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
1 Buy2 Hold0 Sell
Low $37Median $49High $55

The green dot is the last close — the median target sits +37.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 May 2026CitigroupMaintainsNeutral$62 → $44
14 May 2026CitigroupMaintainsNeutral—
15 Apr 2026CitigroupInitiatesNeutral—
7 Nov 2025JP MorganMaintainsOverweight—
29 Aug 2025B of A SecuritiesMaintainsUnderperform—
7 July 2025JP MorganUpgradeOverweight—
25 June 2025Morgan StanleyMaintainsEqual-Weight—
8 May 2025Morgan StanleyMaintainsEqual-Weight—
10 Feb 2025BarclaysMaintainsUnderweight—
17 Dec 2024Morgan StanleyMaintainsEqual-Weight—
12 Nov 2024BarclaysMaintainsUnderweight—
10 Sept 2024JP MorganInitiatesNeutral—
30 Aug 2024B of A SecuritiesMaintainsUnderperform—
10 May 2024BarclaysMaintainsUnderweight—
9 Nov 2023Morgan StanleyMaintainsEqual-Weight—
1 Sept 2023Roth MKMReiteratesBuy—
31 Aug 2023Morgan StanleyMaintainsEqual-Weight—
29 Aug 2023Roth MKMReiteratesBuy—
27 July 2023Morgan StanleyReiteratesEqual-Weight—
4 May 2023Morgan StanleyMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

PAHC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PAHC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Phibro Animal Health Corp. returned −17.1% against +12.2% for the S&P 500, dividends included.

PAHC vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Jan 26Apr 26Jul 26Oct 26PAHCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PAHC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+4.1%
Analysts raising
1
Analysts cutting
0
Fundamentals

Phibro Animal Health Corp. (PAHC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
13.9×

Cheaper than 47% of US stocks

Price / sales
0.9×

Cheaper than 69% of US stocks

Price / book
3.4×

Cheaper than 27% of US stocks

EV / EBITDA
8.6×

Cheaper than 42% of US stocks

Growth & margins
Revenue growth (YoY)
6.3%

Higher than 44% of US stocks

Earnings growth (YoY)
11.3%

Higher than 51% of US stocks

Gross margin
33.9%

Higher than 40% of US stocks

Operating margin
12.7%

Higher than 70% of US stocks

Net margin
6.7%

Higher than 63% of US stocks

Returns & dividend
Return on equity
28.2%

Higher than 86% of US stocks

Return on assets
8.4%

Higher than 89% of US stocks

Dividend yield
1.4%

Higher than 74% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Phibro Animal Health Corp. (PAHC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Phibro Animal Health Corp. has a market value of $1.4B and an enterprise value of $2.1B.

  • Revenue in the twelve months to 30 June 2026: $1.5B. The latest quarter grew 6.3% year on year.

  • Net income over the same four quarters: $99.7M, a 6.6% net margin.

  • Diluted earnings per share, trailing twelve months: $2.44.

  • Free cash flow in the twelve months to 30 June 2026: $9.9M, after $59.1M of capital spending.

  • Phibro Animal Health Corp. spent $19.5M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 40.6M.

  • Trailing P/E: 13.9×; forward P/E: 9.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.37%, paying out 19% of earnings.

  • Phibro Animal Health Corp. employs 2,605 people — $583K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

PAHC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
PAHCPhibro Animal Health Corp.$1.4B92
PCRXPacira Biosciences, Inc.$1.5B100
AMPHAmphastar Pharmaceuticals, Inc.$1.3B94
ALVOAlvotech$1.6B32
ANIPANI Pharmaceuticals, Inc.$1.6B98
HROWHarrow, Inc.$1.1B42
ETONEton Pharmaceuticals, Inc.$1.8B99

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Phibro Animal Health Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PAHC news & analysis

Interpreting Phibro (PAHC) International Revenue Trends

Zacks Investment Research · 9 Nov 2026neutral

The Zacks Investment Research item examines Phibro’s overseas revenue trends and their effects on Wall Street forecasts and the stock’s prospects.

Why it matters — PAHC watchers may find the discussion relevant to how international revenue trends factor into forecasts and assessments of the stock.

Phibro Animal Health Corporation (PAHC) Q1 2027 Earnings Call Transcript

Seeking Alpha · 7 Nov 2026neutral

Seeking Alpha published the transcript of Phibro Animal Health Corporation’s Q1 2027 earnings call, held November 5, 2026. The excerpt identifies company executives and analysts participating but provides no results or discussion details.

Why it matters — The transcript is a source for PAHC watchers seeking details from the company’s first-quarter earnings call, though those details are not included in the excerpt.

Phibro (PAHC) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks Investment Research · 5 Nov 2026neutral

Zacks Investment Research notes that Phibro reported Q1 revenue and EPS for the quarter ended September 2026, and points readers to compare key metrics with Wall Street estimates and year-ago figures. The excerpt does not provide the results or comparisons.

Why it matters — PAHC watchers may find the key-metric comparisons useful for assessing the quarterly performance, but the excerpt gives no figures or outcomes.

Phibro Animal Health (PAHC) Q1 Earnings Match Estimates

Zacks Investment Research · 4 Nov 2026neutral

Phibro Animal Health reported quarterly earnings of $0.79 per share, matching the Zacks Consensus Estimate. Earnings were $0.73 per share a year ago.

Why it matters — PAHC watchers may note that quarterly earnings matched consensus and were higher than the year-ago figure.

Phibro Animal Health Corporation Reports First Quarter Results, Maintains Financial Guidance

Business Wire · 4 Nov 2026positive

Phibro Animal Health reported first-quarter net sales of $386.8 million, up 6% from the prior-year quarter, and net income of $29.5 million, up $3.0 million. The company maintained its financial guidance for the year ending June 30, 2027.

Why it matters — The results and maintained guidance provide PAHC watchers with an update on quarterly performance and the company’s outlook.

FAQ

Frequently asked questions about PAHC stock

What is the PAHC stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Phibro Animal Health Corp. have a median 12-month price target of $49, with estimates ranging from $37 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PAHC stock a buy right now?

Of the 3 analysts covering Phibro Animal Health Corp., 1 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Phibro Animal Health Corp. 92 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PAHC?

As at 17 Nov 2026, Phibro Animal Health Corp. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (97 of 100).

Will PAHC stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +37.7% from the last close, and Ticker Nerd's factor model ranks Phibro Animal Health Corp. 92 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PAHC stock forecast for 2030?

No analyst covering Phibro Animal Health Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PAHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $37 to $55 over the next 12 months.

How has PAHC stock performed over the past year?

Phibro Animal Health Corp. returned -17.1% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Phibro Animal Health Corp. do?

Phibro Animal Health Corporation Class A Common Stock represents ownership in Phibro Animal Health Corporation, a global animal health and mineral nutrition company. Phibro develops, manufactures, and markets products for food-producing and companion animals, supporting sectors such as poultry, swine, beef and dairy cattle, aquaculture, and pets.

What is the latest news on PAHC?

The most recent item we track (Zacks Investment Research, 9 Nov 2026): "Interpreting Phibro (PAHC) International Revenue Trends". The Zacks Investment Research item examines Phibro’s overseas revenue trends and their effects on Wall Street forecasts and the stock’s prospects.

Company

About Phibro Animal Health Corp.

Phibro Animal Health Corporation Class A Common Stock represents ownership in Phibro Animal Health Corporation, a global animal health and mineral nutrition company. Phibro develops, manufactures, and markets products for food-producing and companion animals, supporting sectors such as poultry, swine, beef and dairy cattle, aquaculture, and pets. Its portfolio spans animal health solutions, mineral nutrition products, and performance products used in livestock production and animal care. The company serves customers across the agricultural and veterinary supply chains, where its offerings help address nutrition, health, and productivity needs in animal operations. Phibro Animal Health Corporation is headquartered in Teaneck, New Jersey, and its Class A common stock is one of the company’s primary publicly traded equity classes.

CEO Mr. Daniel M. Bendheim J.D. · 2,605 employees · United States · https://www.pahc.com